Clinical Trials

TILs-001-DC

A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Eligible tumor type: Ovarian Cancer

Sponsor: In-house

PI: Marcus Butler

NCT#: NCT01883297

For more information visit https://clinicaltrials.gov/ct2/show/NCT01883297

TILs-002-MEL

Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma

Eligible tumor type: Metastatic Melanoma

Sponsor: In-house

PI: Marcus Butler

NCT#: NCT01883323

For more information visit https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1

TILs-003-Meso

Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)

Eligible tumor types: malignant pleural mesothelioma

Sponsor: In-house

PI: Marcus Butler

NCT#: NCT02414945

For more information visit https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1

METADUR

An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors

Eligible tumor types: Breast Cancer, Colorectal Cancer, Ovarian Cancer

Sponsor: In-house

PI: Lillian Siu

NCT#: TBD

INSPIRE

INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

Eligible tumor types: metastatic melanoma, triple negative breast cancer, squamous cell cancer of the head and neck, ovarian cancer, solid cancers

Sponsor: In-house

PI: Lillian Siu

NCT#: NCT02644369

For more information visit https://clinicaltrials.gov/ct2/show/NCT02644369

1301-02

Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors

Eligible tumor types:Solid Cancer

Sponsor: In-house (in collaboration with Takara Bio Inc)

PI: Marcus Butler

NCT#: 02869217

For more information visit https://clinicaltrials.gov/ct2/show/NCT02869217

ACTIVATE

Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

Eligible tumor types: ovarian cancer, metastatic melanoma

Sponsor: In-house

PI: Marcus Butler

NCT#: TBD

MG1MA3 with AdMA3

A phase Ib study of MG1 MARABA/MAGE-A3 (MG1MA3) with adenovirus vaccine/MAGE A3 (AdMA3) in combination with the immune checkpoint inhibitor Pembrolizumab in patients with incurable advanced or metastatic MAGE-A3 expressing solid tumors

Eligible tumor types: Incurable advanced or metastatic MAGE-A3 expressing solid tumors

Sponsor: In-house

PI: Marcus Butler

NCT#: TBD

Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

Eligible Tumor Type: acute myeloid leukemia (AML)

Sponsor: In-house

PI: Dr. Mark Minden

NCT#: NCT02483312

For more information visit https://clinicaltrials.gov/ct2/show/NCT02483312